RESUMO
BACKGROUND: Hereditary tyrosinemia type 1 is a rare metabolic condition associated with an increased risk of hepatocellular carcinoma. Nitisinone (2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione, NTBC) treatment has reduced but not eliminated the risk. The delayed initiation of nitisinone treatment, and persistently abnormal α1-fetoprotein (AFP) levels are recognized to be risk factors for late-onset hepatocellular carcinoma. We report three children diagnosed and treated with nitisinone since infancy who developed hepatocellular carcinoma despite long-term normalization of AFP. METHODS: A retrospective review of all patients with tyrosinemia on nitisinone managed at our center was undertaken. Patient demographics, age at diagnosis, duration of therapy, timing of AFP normalization, and radiographic imaging findings were noted. RESULTS: Three patients at our center with tyrosinemia type 1 developed hepatocellular carcinoma 9-13 years after diagnosis despite long-term nitisinone therapy and normalization of AFP. Two patients developed new nodules on imaging with an elevation of AFP leading to the diagnosis and subsequent liver transplant. The third patient proceeded with liver transplant because of a very nodular liver and increasing splenomegaly despite normal AFP and no change in surveillance gadoxetate magnetic resonance imaging. Early hepatocellular carcinoma was found in her liver explant. All three patients were cirrhotic at diagnosis. CONCLUSIONS: Patients with hereditary tyrosinemia type 1, especially those already cirrhotic at diagnosis, remain at high risk of developing hepatocellular carcinoma despite long-term nitisinone therapy and AFP normalization, and warrant close monitoring and surveillance.
Assuntos
Carcinoma Hepatocelular , Neoplasias Hepáticas , Transplante de Fígado , Tirosinemias , Carcinoma Hepatocelular/etiologia , Criança , Cicloexanonas , Feminino , Humanos , Cirrose Hepática/complicações , Neoplasias Hepáticas/diagnóstico , Transplante de Fígado/efeitos adversos , Nitrobenzoatos , Tirosinemias/complicações , Tirosinemias/diagnóstico , alfa-FetoproteínasRESUMO
OBJECTIVES: Autoimmune liver disease (AILD) incorporates primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), and autoimmune sclerosing cholangitis (ASC). ASC is a condition that includes overlap of AIH and PSC. We investigate changes in practice in relation to diagnosis and phenotype over 2 time periods. METHODS: Retrospective chart review was conducted from January 2000 to 2016. Data were divided into two 8-year cohorts, CI and C2. RESULTS: Data were collected in 75 children, 29 in 2000-2007 (C1) and 46 in 2008-2016 (C2). Presenting AILD type was AIH in 59%, ASC in 10%, and PSC in 31%. Final AILD type was AIH in 53%, ASC in 16%, and PSC in 31%. When comparing C1 to C2, those with AIH decreased (65% vs 45%) and those with ASC increased (14% vs 18%). Use of magnetic resonance cholangio-pancreatography increased from 34% in C1 to 65% in C2. Advanced liver disease on biopsy was noted in 53% of all children at presentation. Only 5 female children progressed to liver transplant (3 ASC-IBD [inflammatory bowel disease]; 1 PSC-IBD; 1 AIH). Colonoscopy performance increased from 48% in C1 to 63% in C2 with diagnosis of AILD-IBD increasing from 31% to 52%. Right-sided disease was present in 46% and macroscopic rectal sparing in 36% of those with ulcerative colitis (UC). Colectomy was required in 3 children with large duct PSC-IBD. CONCLUSIONS: PSC and ASC are increasing in relevance along with IBD and reflect increasing performance of magnetic resonance cholangio-pancreatography and colonoscopy. Large duct PSC and ASC with IBD are risk factors for colectomy and along with female gender, for liver transplant.
Assuntos
Colangiopancreatografia por Ressonância Magnética/tendências , Colangite Esclerosante/diagnóstico por imagem , Colangite Esclerosante/imunologia , Hepatite Autoimune/diagnóstico por imagem , Adolescente , Alanina Transaminase/sangue , Fosfatase Alcalina/sangue , Anticorpos Anticitoplasma de Neutrófilos/sangue , Anticorpos Antinucleares/sangue , Aspartato Aminotransferases/sangue , Austrália , Autoanticorpos/sangue , Biópsia , Criança , Pré-Escolar , Colangiopancreatografia por Ressonância Magnética/estatística & dados numéricos , Colangite Esclerosante/patologia , Colangite Esclerosante/cirurgia , Colectomia , Colonoscopia/estatística & dados numéricos , Colonoscopia/tendências , Feminino , Hepatite Autoimune/patologia , Hepatite Autoimune/cirurgia , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/diagnóstico por imagem , Doenças Inflamatórias Intestinais/cirurgia , Fígado/patologia , Transplante de Fígado , Masculino , Músculo Liso/imunologia , Fenótipo , Estudos Retrospectivos , gama-Glutamiltransferase/sangueRESUMO
AIM: Transient elastography (TE) is a rapid, non-invasive, reproducible assessment of liver fibrosis by liver stiffness measurement (LSM). Uncertainty remains regarding utility in children, unsedated and <6 years of age. The importance of general health at the time of study has not been addressed. We report our experience of TE in unsedated control children, impact of intercurrent illness and using new published reliability criteria. METHODS: From April 2011 to March 2013, 173 studies were performed in unsedated, healthy control children and children with intercurrent illness without detectable liver disease presenting to the Royal Children's Hospital, Brisbane, Australia. LSM reliability was assessed using interquartile range/median (IQR/M ≤ 30%) of 10 valid measurements. RESULTS: A total of 123 (F:M, 52:71) of 173 studies (71.1%) gave reliable results. In children 0-2 years reliability was 36%, and >2 years reliable results were obtained in ~80%. LSM increased with age; 0-2 years (3.5 ± 0.5 kPa), 3-5 years (3.8 ± 0.3 kPa) and 6-11 years (4.1 ± 0.2 kPa) with healthy older children 12-18 years similar to adults (4.5 ± 0.2 kPa). LSM did not vary with gender (female, 4.5 ± 0.2 vs. male, 4.8 ± 0.2 kPa). Children with intercurrent, non-hepatological illnesses had higher LSM (5.2 ± 0.2 kPa (range, 2.8-11.1 kPa)) compared to healthy children ((4.1 ± 0.1 kPa, range, 2.1-6.3 kPa); P = 0.0001). CONCLUSIONS: TE in unsedated children is feasible from infancy but most reliable after 2 years. Intercurrent illness increases LSM; hence, study context is important when interpreting results.
Assuntos
Técnicas de Imagem por Elasticidade , Cirrose Hepática/diagnóstico , Adolescente , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Hepatopatias/diagnóstico , MasculinoAssuntos
Colangite Esclerosante , Colite Ulcerativa , Colite , Microbioma Gastrointestinal , Criança , Humanos , VancomicinaRESUMO
Congenital diarrhea and enteropathies (CODEs) constitute a group of rare genetic disorders characterized by severe diarrhea and malabsorption in the neonatal period or early infancy. Timely diagnosis and treatment is essential to prevent life-threatening complications, including dehydration, electrolyte imbalance, and malnutrition. This review offers a simplified approach to the diagnosis of CODEs, with a specific focus on microvillus inclusion disease (MVID), congenital tufting enteropathy (CTE), congenital chloride diarrhea (CLD), and congenital sodium diarrhea (CSD). Patients with CODEs typically present with severe watery or occasionally bloody diarrhea, steatorrhea, dehydration, poor growth, and developmental delay. Therefore, it is crucial to thoroughly evaluate infants with diarrhea to rule out infectious, allergic, or anatomical causes before considering CODEs as the underlying etiology. Diagnostic investigations for CODEs encompass various modalities, including stool tests, blood tests, immunological studies, endoscopy and biopsies for histology and electron microscopy, and next-generation sequencing (NGS). NGS plays a pivotal role in identifying the genetic mutations responsible for CODEs. Treatment options for CODEs are limited, often relying on total parenteral nutrition for hydration and nutritional support. In severe cases, intestinal transplantation may be considered. The long-term prognosis varies among specific CODEs, with some patients experiencing ongoing intestinal failure and associated complications. In conclusion, the early recognition and accurate diagnosis of CODEs are of paramount importance for implementing appropriate management strategies. Further research and advancements in genetic testing hold promise for enhancing diagnostic accuracy and exploring potential targeted therapies for these rare genetic disorders.
Assuntos
Diarreia , Síndromes de Malabsorção , Humanos , Diarreia/terapia , Diarreia/etiologia , Diarreia/congênito , Síndromes de Malabsorção/terapia , Síndromes de Malabsorção/diagnóstico , Síndromes de Malabsorção/genética , Recém-Nascido , Lactente , Erros Inatos do Metabolismo/diagnóstico , Erros Inatos do Metabolismo/terapia , Erros Inatos do Metabolismo/genética , Mucolipidoses/diagnóstico , Mucolipidoses/terapia , Mucolipidoses/genética , Microvilosidades/patologia , Enteropatias/diagnóstico , Enteropatias/terapia , Enteropatias/genética , Anormalidades Múltiplas , Diarreia InfantilRESUMO
BACKGROUND: Current diagnostic methods for the diagnosis of Cystic fibrosis (CF)-associated liver disease (CFLD) are non-specific and assessment of disease progression is difficult prior to the advent of advanced disease with portal hypertension. This study investigated the potential of Supersonic shear-wave elastography (SSWE) to non-invasively detect CFLD and assess hepatic fibrosis severity in children with CF. METHODS: 125 children were enrolled in this study including CFLD (nâ¯=â¯55), CF patients with no evidence of liver disease (CFnoLDâ¯=â¯41) and controls (nâ¯=â¯29). CFLD was diagnosed using clinical, biochemical and imaging best-practice guidelines. Advanced CFLD was established by the presence of portal hypertension and/or macronodular cirrhosis on ultrasound. Liver stiffness measurements (LSM) were acquired using SSWE and diagnostic performance for CFLD detection was evaluated alone or combined with aspartate aminotransferase-to-platelet ratio index (APRI). RESULTS: LSM was significantly higher in CFLD (8.1â¯kPa, IQRâ¯=â¯6.7-11.9) versus CFnoLD (6.2â¯kPa, IQRâ¯=â¯5.6-7.0; P <â¯0.0001) and Controls (5.3â¯kPa, IQRâ¯=â¯4.9-5.8; Pâ¯<â¯0.0001). LSM was also increased in CFnoLD versus Controls (Pâ¯=â¯0.0192). Receiver Operating Characteristic (ROC) curve analysis demonstrated good diagnostic accuracy for LSM in detecting CFLD using a cut-offâ¯=â¯6.85â¯kPa with an AUCâ¯=â¯0.79 (Sensitivityâ¯=â¯75%, Specificityâ¯=â¯71%, Pâ¯<â¯0.0001). APRI also discriminated CFLD (AUCâ¯=â¯0.74, Pâ¯=â¯0.004). Classification and regression tree modelling combining LSMâ¯+â¯APRI showed 14.8 times greater odds of accurately predicting CFLD (AUCâ¯=â¯0.84). The diagnostic accuracy of SSWE for discriminating advanced disease was excellent with a cut-offâ¯=â¯9.05â¯kPa (AUCâ¯=â¯0.95; Pâ¯<â¯0.0001). CONCLUSIONS: SSWE-determined LSM shows good diagnostic accuracy in detecting CFLD in children, which was improved when combined with APRI. SSWE alone discriminates advanced CFLD.
Assuntos
Aspartato Aminotransferases/sangue , Fibrose Cística , Técnicas de Imagem por Elasticidade/métodos , Cirrose Hepática , Fígado , Contagem de Plaquetas/métodos , Biomarcadores/sangue , Criança , Fibrose Cística/sangue , Fibrose Cística/complicações , Fibrose Cística/fisiopatologia , Progressão da Doença , Feminino , Humanos , Fígado/diagnóstico por imagem , Fígado/fisiopatologia , Cirrose Hepática/sangue , Cirrose Hepática/diagnóstico , Cirrose Hepática/etiologia , Masculino , Gravidade do Paciente , Prognóstico , Reprodutibilidade dos Testes , Índice de Gravidade de DoençaRESUMO
OBJECTIVE: Infliximab (IFX) has an established role in Crohn's disease (CD), with serum trough levels of IFX (TLI) increasingly used to optimise dosing. We report the utility of routine, proactive TLI in children on combination therapy with immunosuppression (IS) from a single paediatric centre. METHODS: This is a retrospective chart review of all children with CD receiving IFX therapy conducted betweenJanuary 2014-May 2017. Clinical phenotype, duration of therapy, TLI (µg/mL), drug antibodies, type of IS, biomarkers and changes in management were recorded. RESULTS: 60 children (8-17 years; median 14.1 years) had 206 TLIs recorded. 56/60 (93%) were on IS, with 5/60 (8%) developing antidrug antibodies (ADAs). 63/206 TLIs were recorded duringan episode of relapse (median 3.0 µg/mL) vs 143/206 TLIs recorded in remission (median 5.2 µg/mL). For children with TLI <3 µg/mL, 31/63 (49%) were in relapse vs 30/143 (21%) in remission. For children with TLI >7 µg/mL, 7/63 (11%) were in relapse vs 46/143 (32%) in remission. Change in management resulted from 43/206 (21%) TLIs in 31/60 (52%) children: 21 dose escalations, 12 de-escalations and 10 changed to adalimumab. Of 31 postinduction TLIs, 15/17 (88%) children with TLI >7 µg/mL achieved clinical and biochemical remission for the duration of therapy (median 14 months), while 4/5 (80%) children with TLI <3 µg/mL required early dose escalation. Combination therapy with thiopurines (TP) (median TLI 4.9 µg/mL) versus methotrexate (MTX) (median TLI 5.2 µg/mL) achieved comparable levels with no difference in relapse frequency. CONCLUSIONS: Routine, proactive TLIs guide optimal management in children with CD. Postinduction and during maintenance, levels <3 µg/mL were associated with relapse and levels >7 µg/mL with sustained remission. Combination IS with TP and MTX appears to offer comparable TLI and ADA rates.